Anavex Life Sciences (AVXL) Net Cash Flow (2010 - 2025)

Anavex Life Sciences (AVXL) has 16 years of Net Cash Flow data on file, last reported at $29.2 million in Q4 2025.

• For the quarter ending Q4 2025, Net Cash Flow rose 355.63% year-over-year to $29.2 million; the trailing twelve-month figure through Dec 2025 stood at $11.0 million (up 147.73% YoY), and the FY2025 full-year result was -$29.6 million, down 57.19% from the prior year.
• Net Cash Flow improved to $29.2 million in Q4 2025, from $1.4 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $81.7 million in Q2 2021 to a low of -$14.6 million in Q2 2025.
• A 5-year average of $4.2 million and a median of -$2.4 million in 2021 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow surged 7636.27% in 2021 and sank 2218.57% in 2025, its largest moves.
• Tracing AVXL's Net Cash Flow over 5 years: stood at -$961390.0 in 2021, then slumped by 475.83% to -$5.5 million in 2022, then plunged by 31.12% to -$7.3 million in 2023, then plunged by 57.21% to -$11.4 million in 2024, then surged by 355.63% to $29.2 million in 2025.
• Business Quant data shows AVXL's Net Cash Flow at $29.2 million in Q4 2025, $1.4 million in Q3 2025, and -$14.6 million in Q2 2025.